Latest Breaking News On - Meso scale engineered molecules - Page 1 : comparemela.com
RubrYc Therapeutics Announces Series A2 Preferred Equity Financing, Collaboration, and RTX-003 License with iBio, Inc
q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.
RubrYc Therapeutics announces Series A2 Preferred equity financing, collaboration, and RTX-003 license with iBio, Inc
antaranews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from antaranews.com Daily Mail and Mail on Sunday newspapers.
RubrYc Therapeutics, Inc : RubrYc Therapeutics informiert über Finanzierung mit Vorzugskapital der Serie A2, Zusammenarbeit und RTX-003-Lizenz mit iBio, Inc
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Redirecting to RubrYc Therapeutics Announces a Research Collaboration and License Option Agreement With Zai Labs
q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.
Search jobs RubrYc Therapeutics Announces a Research Collaboration and License Option Agreement With Zai Labs
SAN CARLOS, Calif. (BUSINESS WIRE) RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies, today announced that it has entered into a research collaboration and license option agreement with Zai Labs, Inc. for the use of RubrYc’s Meso-scale Engineered Molecules (MEMs) platform, to identify monoclonal antibodies with enhanced biological function for an undisclosed oncology target.
Under the terms of the agreement RubrYc and Zai Labs will collaborate to identify product candidates using RubrYc’s Discovery Engine, which leverages machine learning and structural data to identify antibodies that bind to subdominant epitopes and exhibit differentiated activity. Upon exercise of the license option Zai Labs would have exclusive global rights to develop and commercialize product(s) of the Research Colla